Business
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Entered into Clinical Trial Collaboration and Supply Agreement with Amgen to clinically evaluate IDE397, IDEAYA's investigational MAT2A inhibitor, in
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"Entered into Clinical Trial Collaboration and Supply Agreement with Amgen to clinically evaluate IDE397, IDEAYA's investigational MAT2A inhibitor, in combination with AMG 193, Amgen's investigational MTA-Cooperative PRMT5 inhibitor, in MTAP-null solid tumorsPotential first-in-class Synthetic Lethality (SL-SL) Combination targets two distinct, mechanistically complementary, nodes of MTAP methylation pathwayMTAP deletion patient population is estimated to represent approximately 15% of solid tumors, reflecting the potential for significant patient impact with the SL-SL combinationAmgen will sponsor the Phase 1 clinical combination trial with IDEAYA and Amgen jointly sharing costs of the studySOUTH SAN FRANCISCO, Calif., July 27, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397, its investigational, potential best-in-class, small molecule MAT2A inhibitor, with Amgen's AMG 193, an investigational small molecule MTA-cooperative inhibitor of PRMT5, in a Phase 1 clinical trial. \n\n \n \n \n \n \n \n\n \n\"This clinical collaboration with Amgen builds on IDEAYA's ongoing clinical evaluation of IDE397 as monotherapy and in selected combinations in our Phase 1/2 clinical trial, including with taxanes and pemetrexed. We are pleased to collaborate with Amgen to also evaluate the MAT2A-PRMT5 synthetic lethality combination in the clinic,\" said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.\n\"Mechanistically, each of MAT2A and PRMT5 are synthetic lethal with MTAP gene deletion in tumors. The synthetic lethality of each of these targets provides a complementary approach for targeting MTAP-null tumors,\" said Dr. Michael White, Ph.D., Senior Vice President and Chief Scientific Officer, IDEAYA Biosciences. \nIDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), in patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion. The MTAP deletion patient population is estimated to represent approximately 15% of solid tumors, including approximately 15% o...